This summary is based on the presentation of Richard Pratley, MD (Orlando, FL, US) at the ESC Congress 2024 - Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease.
People with T2D and CKD have a high risk of kidney failure and CV outcomes. In the FLOW trial, treatment with semaglutide reduced the composite outcome of kidney events or CV mortality in people with T2D and CKD compared with placebo.
In this prespecified analysis of FLOW, the effects of semaglutide versus placebo on HF events were evaluated in patients with T2D and DM2.
The FLOW trial was a multinational, randomized controlled clinical trial in which 3533 adults with T2D and CKD were randomized in a 1:1 ratio to once-weekly semaglutide 1 mg or to placebo on top of standard care. FLOW was an event-driven trial and was stopped early after meeting efficacy criteria. Median follow-up was 3.4 years.
The main HF outcome was a composite of time to first occurrence of HF events, defined as new onset or worsening HF leading to hospitalization for HF or urgent visit, or cardiovascular mortality.
HF status at baseline
Main outcomes
In this prespecified analysis of FLOW, semaglutide reduced the composite of HF events or cardiovascular mortality in patients with T2D and CKD compared with placebo, regardless of baseline history of HF. A consistent effect was observed across prespecified clinically relevant subgroups.
- Our reporting is based on the information provided at the ESC Congress 2024 -